JP2022159061A - Chylomicron production-related gene expression regulator - Google Patents

Abstract

To provide a chylomicron production-related gene expression regulator.SOLUTION: A chylomicron production-related gene expression regulator contains at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan.SELECTED DRAWING: None

Description

There is an application for exception to loss of novelty

The present invention relates to a chylomicron production-related gene expression regulator and the like.

Dietary lipids are converted into a form suitable for absorption in the intestinal lumen and absorbed by intestinal epithelial cells. In the intestinal epithelial cells, absorbed lipid undergoes various transformations, finally producing chylomicrons, which are lipid transport particles. Chylomicrons are excreted from intestinal epithelial cells into the circulatory system consisting of lymphatics and blood vessels and are responsible for lipid transport throughout the body. In this way, chylomicrons are responsible for the first part of the circulation and transport of exogenous lipids in the body, so it is thought that suppressing their production will fundamentally suppress the circulation and transport of lipids in the body.

Euglena is a microalga belonging to the genus Euglena (= Euglena genus) and is used as a food material. In addition, application of Euglena extract to the skin is also performed (Patent Document 1). Paramylon is a β-1,3-glucan produced by Euglena, and is reported to be useful for wound healing and allergy suppression. However, the relationship between euglena or β-1,3-glucan and chylomicron production is still unknown.

Japanese Patent Publication No. 2008-526954

An object of the present invention is to provide a chylomicron production-related gene expression regulator.

As a result of intensive research in view of the above problems, the present inventors have found that a chylomicron production-related gene containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan The inventors have found that the above problems can be solved by using an expression regulator. As a result of further research based on this knowledge, the present invention was completed. That is, the present invention includes the following aspects.

Section 1. A chylomicron production-related gene expression regulator containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan.

Section 2. Item 2. The chylomicron production-related gene expression regulating agent according to Item 1, containing at least one selected from the group consisting of euglena, paramylon, and processed products of paramylon.

Item 3. It contains Euglena and/or Paramylon, and the Euglena is Euglena gracilis and/or the Paramylon is Euglena gracilis-derived paramylon,
Item 3. The chylomicron production-related gene expression regulator according to Item 1 or 2.

Section 4. It contains the Euglena and / or paramylon, and the Euglena is Euglena gracilis EOD-1 strain (accession number FERM BP-11530) and / or the paramylon is Euglena gracilis EOD-1 strain (accession number FERM BP- 11530), which is a paramylon derived from
Item 3. The chylomicron production-related gene expression regulator according to Item 1 or 2.

Item 5. Items 1 to 1 for use in suppressing the expression of at least one chylomicron production-related gene selected from the group consisting of SR-B1, FABP, ACAT, MGAT, Apo-A IV, ABCA1, Lipase, CLPS, and PAP 5. The chylomicron production-related gene expression regulator according to any one of 4.

Item 6. Item 6. The chylomicron production-related gene expression regulating agent according to any one of Items 1 to 5, for use in regulating the expression of a chylomicron production-related gene in intestinal tissue.

Item 7. Item 7. Chylomicron production-related gene expression regulation according to any one of Items 1 to 6, for use in at least one selected from the group consisting of suppression of chylomicrons production, suppression of lipid absorption in the intestine, and suppression of lipids in chylomicrons. agent.

Item 8. Item 8. The chylomicron production-related gene expression regulating agent according to Item 6 or 7, wherein the intestine is the small intestine.

Item 9. Obesity prevention and/or improvement, body fat burning promotion, fatty acid metabolism activation, fatty acid β-oxidation induction, insulin resistance prevention and/or improvement, diabetes prevention and/or improvement, dyslipidemia prevention and/or improvement, fatty liver prevention and/or improvement, prevention and/or improvement of arteriosclerosis, improvement of endurance, prevention and/or improvement of atopic dermatitis, promotion of fatty acid metabolism, normalization of blood lipids, suppression of fatty liver, promotion of energy consumption, inflammation Items 1 to 8 for use in at least one selected from the group consisting of suppression of body fat and/or visceral fat, suppression of cholesterol, suppression of blood sugar level elevation, suppression of overweight, and suppression of BMI Chylomicron production-related gene expression regulator according to any one of .

Item 10. Item 10. The chylomicron production-related gene expression regulator according to any one of Items 1 to 9, which is a food composition, dietary supplement, food additive, or pharmaceutical.

Item 11. Item 11. The chylomicron production-related gene expression regulator according to any one of Items 1 to 10, which is an oral composition.

Item 12. A chylomicron production inhibitor containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan.

Item 13. An inhibitor of lipid absorption in the intestine, containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan.

Item 14. A chylomicron lipid inhibitor containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan.

Item 14. Obesity prevention and/or improvement, body fat burning promotion, fatty acid metabolism activation, fatty acid β-oxidation induction, insulin resistance prevention and/or improvement, diabetes prevention and/or improvement, dyslipidemia prevention and/or improvement, fatty liver prevention and/or improvement, prevention and/or improvement of arteriosclerosis, improvement of endurance, prevention and/or improvement of atopic dermatitis, promotion of fatty acid metabolism, normalization of blood lipids, suppression of fatty liver, promotion of energy consumption, inflammation Item 12-14 for use in at least one selected from the group consisting of suppression of body fat and/or visceral fat, suppression of cholesterol, suppression of rise in blood sugar level, suppression of overweight, and suppression of BMI An inhibitor according to any one of

INDUSTRIAL APPLICABILITY According to the present invention, a chylomicron production-related gene expression regulator can be provided.

1 is a graph showing measurement results of expression levels of chylomicron production-related genes (SR-B1, FABP, ACAT, MGAT, Apo-A IV, ABCA1) in Test Example 1. FIG. The control group was a group that received a high-fat diet supplemented with lard, and the test group was a group that received a high-fat diet supplemented with paramylon instead of the cellulose contained in the high-fat diet. The horizontal axis indicates the measured gene. The vertical axis indicates the relative signal for each gene when the signal in the control group is set to 1. 2 is a graph showing measurement results of expression levels of chylomicron production-related genes (Lipase, CLPS, PAP) in Test Example 1. FIG. The control group was a group that received a high-fat diet supplemented with lard, and the test group was a group that received a high-fat diet supplemented with paramylon instead of the cellulose contained in the high-fat diet. The horizontal axis indicates the measured gene. The vertical axis indicates the relative signal for each gene when the signal in the control group is set to 1.

As used herein, the expressions "contain" and "include" include the concepts "contain", "include", "consist essentially of" and "consist only of".

In one aspect of the present invention, a chylomicron production-related gene expression regulator (this specification contains at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan) In the book, it may be indicated as "the agent of the present invention"). This will be explained below.

1. Euglena Euglena is a microalgae belonging to the genus Euglena (= Euglena genus), and is not particularly limited as long as it is. Specific examples of Euglena include Euglena gracilis , Euglena longa , Euglena caudata , Euglena oxyuris , Euglena tripteris , Euglena proxima , Euglena viridis , Euglena sociabilis , Euglena ehrenbergii , Euglena deses , Euglena pisciformis , Euglena spirogyra , Euglena acus , Euglena geniculata , Euglena intermedia , Euglena mutabilis , Euglena sanguinea , Euglena stellata , Euglena terricola , Euglena klebsi , Euglena rubra , Euglena cyclopicola and the like. Among these, from the viewpoint that the effects of the present invention can be more reliably exhibited, Euglena gracilis is preferable, and Euglena gracilis EOD-1 strain [as of June 28, 2013, Independent Administrative Agency Product Evaluation Under the provisions of the Budapest Treaty, the Patent Organism Depositary Center, National Institute of Technology, NITE-IPOD (2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818, Room 120) under the provisions of the Budapest Treaty, with the accession number FERM BP-11530. Internationally deposited].

The form of Euglena is not particularly limited as long as it contains the cell body of Euglena or most of its components. Examples of the form of Euglena include dry powder form of Euglena, suspension of Euglena, Euglena extract, etc. Among them, dry powder form of Euglena is preferred.

The paramylon content of Euglena in a dry state is, for example, 50% or more, preferably 60% or more, and more preferably 70% or more.

Euglena may be used singly or in combination of two or more.

2. β-1,3-Glucan and paramylon β-1,3-glucan have a single sugar chain (or sugar chain structure) consisting of glucose linked only by β1,3 bonds as the main chain. There are no particular restrictions. β-1,3-Glucans include not only straight-chain ones but also branched-chain ones.

The weight average molecular weight of the β-1,3-glucan derivative is not particularly limited, but is, for example, 1×10 ⁴ to 2×10 ⁶ , preferably 5×10 ⁴ to 1×10 ⁶ , more preferably 1×10 ⁵ to There are 1×10 ⁶ . In addition, the weight average molecular weight can be measured by the GPC method.

The β-1,3-glucan may be one obtained by chemical synthesis, but natural β-1,3-glucan produced by various organisms is preferable from the viewpoint of availability. Examples of natural β-1,3-glucans include paramylon, curdlan, laminaran, callose, lentinan, schizophyllan and the like. Among these, paramylon is particularly preferred. Paramylon will be described below.

Paramylon is a β-1,3-glucan derived from Euglena, and is not particularly limited as far as it is concerned.

Euglena from which paramylon is derived is the same as described in the above "1. Euglena".

The mass average molecular weight of paramylon is not particularly limited, but is, for example, 1×10 ⁴ to 5×10 ⁶ , preferably 2×10 ⁴ to 1×10 ⁶ , more preferably 5×10 ⁴ to 1×10 ⁶ , still more preferably. is between 1×10 ⁵ and 5×10 ⁵ .

The mass average molecular weight can be measured by SEC-MALS analysis under the following conditions:
Detector: Multi-angle scattering detector (DAWN HELEOS II manufactured by Wyatt Technology) Differential refractometer detector (Optilab T-rEX manufactured by Wyatt Technology) Column used: 2 TSKgel α-M (manufactured by Tosoh)
Mobile phase: DMSO with 0.05M potassium bromide
Flow rate: 0.5 mL/min.

In Euglena cells, paramylon normally exists as paramylon particles, which are highly-accumulated triple-helix structures formed by β-1,3-glucan chains on certain regular bases.

The shape of the paramylon particles is not particularly limited, but is usually a flattened spheroid.

The particle size distribution of paramylon particles is not particularly limited, but is, for example, 0.5 to 15 μm, preferably 1 to 6 μm. Also, the average particle size of the paramylon particles is not particularly limited, but is, for example, 1 to 10 μm, preferably 2 to 4 μm.

The form of paramylon is not particularly limited as long as it contains paramylon. Examples of the form of Euglena include a dry powder form of paramylon, a suspension of paramylon, etc. Among them, a dry powder form of paramylon is preferred.

Paramylon may be used singly or in combination of two or more.

3. Method for Producing Euglena and Paramylon Euglena can be prepared in large quantities by a method including a step of culturing Euglena contained in a liquid (culturing step). The culture step can be performed, for example, according to a known method (eg, the method described in Japanese Patent No. 5883532). In the culturing step, typically, Euglenoid microalgae are cultured under aerobic conditions while stirring a liquid (culture solution) containing water, Euglena, and nutrients that Euglena can use.

Nutrients include sugars (monosaccharides such as glucose (glucose) and fructose (fructose)), minerals (such as sodium, potassium, magnesium, calcium, iron, zinc, molybdenum, copper, phosphorus, nitrogen, sulfur, or boron). etc.), B vitamins (e.g. vitamin B1 (thiamine), vitamin B2 (riboflavin), niacin, pantothenic acid, vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine), vitamin B12 (cyanocobalamin), folic acid, biotin, etc.) be done. The concentration of nutrients in the culture medium is not particularly limited as long as it is a concentration that allows Euglena to survive, proliferate, and the like.

The light conditions for the culturing step are not particularly limited, and the culturing step may be performed under either light or dark conditions. When cultured in heterotrophic culture, it is cultured under dark conditions. As a light condition, a normal light intensity for growing algae can be adopted. Dark conditions include, for example, less than 10 μmol/m ² /s, preferably completely dark conditions with no light.

The culture temperature in the culture step is not particularly limited as long as it is a temperature at which Euglena can grow. As the culture temperature (temperature of the culture solution), for example, 20°C to 35°C is adopted.

The pH of the liquid in the culturing step is not particularly limited as long as it allows Euglena to proliferate. A pH of 3.0 to 5.5, for example, is adopted as the pH at which Euglena can grow.

After the culturing step, it is preferable to concentrate Euglena by liquid centrifugation, gravity separation, or the like. The obtained Euglena can be subjected to additional processing (for example, suspension in liquid, dispersion in water or oil, extract extraction, dry powderization, etc.) depending on the desired form.

Paramylon particles can be produced by separating, isolating, or purifying from Euglena according to or according to known methods (eg, the method described in Japanese Patent No. 5883532). Paramylon particles can be easily obtained, for example, by recovering intracellular components obtained by disrupting Euglena cell membranes. Moreover, if necessary, the paramylon particles may be purified. Various methods for purifying paramylon particles are known (eg, Japanese Patent No. 5883532), and can be performed according to those methods. Examples of the purification step include a surfactant treatment step and a washing step. The resulting Euglena can be subjected to additional processing (eg, suspension in liquid, dispersion in water or oil, dry powderization, etc.) depending on the desired form.

Four. Paramylon-processed product The paramylon-processed product is obtained by subjecting paramylon to a processing treatment, such as a physical treatment or a chemical treatment, and is not particularly limited as long as it is processed. Examples of paramylon-processed products include fiberized paramylon and amorphous paramylon. Amorphous paramylon can be obtained by chemical treatment according to or in accordance with a known method, for example, using the method described in JP-A-2011-184592.

Fiberized paramylon is preferable as the processed paramylon. Fiberized paramylon will be described below.

Fibrosis paramylon is Euglena-derived β-1,3-glucan, and is not particularly limited as long as it is in a fibrous form. Until now, amorphous paramylon obtained by chemically treating paramylon particles (alkali treatment, etc.) has been reported. Since it is an amorphous mass, it is not included in fibrillated paramylon.

The weight average molecular weight of fiberized paramylon is not particularly limited, but is, for example, 1×10 ⁴ to 2×10 ⁷ , preferably 1×10 ⁵ to 5×10 ⁵ .

The weight average molecular weight can be measured by SEC-MALS analysis by the following method: Detector: Multi-angle scattering detector (DAWN HELEOS II manufactured by Wyatt Technology) Differential refractometer detector (Optilab T manufactured by Wyatt Technology -rEX) Columns used: 2 TSKgel α-M (manufactured by Tosoh)
Mobile phase: DMSO with 0.05M potassium bromide
Flow rate: 0.5 mL/min.

The fiber diameter of the fiberized paramylon is not particularly limited, but is, for example, 10 to 500 nm, preferably 20 to 300 nm, more preferably 50 to 200 nm. The diameter of the fibers of fibrillated paramylon can usually be measured based on an electron microscope image of fibrillated paramylon.

The settling volume of fibrillated paramylon in water is not particularly limited, but is, for example, 30 to 300 mL/g, preferably 50 to 250 mL/g, more preferably 70 to 200 mL/g.

Settling volume in water can be measured according to or in accordance with the following method:
Measure according to the method described in "Supervised by the Japan Dietary Fiber Society, Edited by the Japan Dietary Fiber Society Editorial Committee (2008) Dietary Fiber -Basics and Applications- 3rd Edition, p.111 Daiichi Publishing, Tokyo" . Specifically, it is as follows. Weigh 125 mg of the sample slurry test sample into a 25 mL volume plastic tube, calculated as dry mass, and shake the plastic tube vigorously by hand to agitate the contents. Then transfer the contents to a 25 mL graduated cylinder and add pure water to bring the volume to 25 mL. After stirring the liquid in the graduated cylinder, leave it at 37°C for 24 hours. This causes the sample to settle, resulting in two layers, one containing mainly the precipitated sample (lower layer) and the other containing mainly water (upper layer), separated through the interface. Calculate the volume of the lower layer from the scale of the graduated cylinder, divide the obtained volume by the sample mass (dry mass), and calculate the volume settled in water (mL/g). Perform the test 3 or 4 times and calculate the average value and standard deviation.

Fibrillating paramylon has a relatively high resistance to enzymatic degradation. For example, the amount of monomer (glucose) produced by the decomposition of β-glucanase is, for example, 0.1-50 mg, preferably 1-10 mg, per 1 g of fibrillated paramylon.

This amount can be measured according to or according to the following methods:
Reaction solution [test substance 30 mg (dry weight), buffer solution (B0156 manufactured by Tokyo Chemical Industry Co., Ltd., potassium hydrogen phthalate-sodium hydroxide buffer (pH 4.0)) 5 mL, enzyme solution (endo- 1,3-β-Glucanase (enzyme content: 50 units/mL)) 0.1 mL, pure water, reaction volume 10 mL], shake horizontally at 40°C for 24 hours at 45 rpm. After shaking, immediately store frozen and lyophilize for concentration. After freeze-drying, add 0.5 mL of pure water to each sample and stir (20-fold concentration). The operation of centrifuging (10000G, 5 minutes, 4°C) and collecting the supernatant is repeated twice. The glucose concentration in the recovered supernatant is measured using a measurement kit (Glucose CII-Test Wako manufactured by Wako Pure Chemical Industries, Ltd.). Based on the measured values, calculate the amount of glucose produced (mg) per 1 g of the test substance.

Fiberized paramylon has relatively low solubility in alkaline solutions. For example, fiberized paramylon does not dissolve in 0.1-0.3M sodium hydroxide aqueous solution. Here, "does not dissolve" means, for example, that the absorbance (660 nm) of the solution after suspending the fibrillated paramylon in the aqueous solution (for example, immediately after to 1 hour later) is, for example, 0.1 or more, preferably 1.0. means greater than or equal to

Solubility can be measured according to or in accordance with the following methods:
Suspend 250 mg (dry weight) of the test substance in 10 mL of test solution (pure water, 0.1 M NaOH aqueous solution, 0.3 M NaOH aqueous solution) in a vial. The absorbance at 660 nm of the liquid in the vial is measured after shaking the vial vigorously by hand for 20 seconds and after shaking on a shaker at 80 rpm for 1 hour. The absorbance is measured using a spectrophotometer V-730 manufactured by JASCO Corporation.

The relative value of crystallinity of fiberized paramylon to granular paramylon (crystallinity of fiberized paramylon/crystallinity of granular paramylon) is, for example, 0.60 to 0.90, preferably 0.65 to 0.80.

Crystallinity can be measured according to or according to the following methods:
XRD measurement is performed on the test substance. The conditions are as follows. Equipment: PANalytical X'Pert3 Powder, tube voltage: 45kV, tube current: 40mA, measurement range: 5.005 to 50.018°, measurement interval: 0.013°, analysis software: HighScore. The degree of crystallinity is analyzed by the ratio of the intensity of the amorphous part to the intensity of the crystalline part at 2θ=5 to 80°. The analysis was performed after removing the background from each measurement sample (background setting Auto, venting factor 0, granularity 100), and the amorphous part was determined by the tangent line passing through 2θ = 14, 29°. do. The pending factor and granularity condition for determining each amorphous portion is 0/20.

Fiberized paramylon may be in a form dispersed in a solvent such as water, or may be in a dry form. Fiberized paramylon, even in dry form, can be redispersed in water.

As used herein, the term "dry form" indicates that the water content is 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less.

As the fibrillated paramylon, a fibrillated product of paramylon particles obtained by physically fibrillating the paramylon particles can be preferably used. In addition, a fibrillated product of Euglena obtained by applying this fibrillation treatment to Euglena can also be used as fiberized paramylon.

The fibrillation treatment hardly breaks the hydrogen bonds of β-1,3-glucans present in the paramylon particles (for example, 10% or less, 5% or less, 2% or less of the hydrogen bonds of β-1,3-glucans , 1% or less), or unraveling part or all of the β-1,3-glucan chains present in the paramylon particles or the triple helix structure formed by them. is not particularly limited as long as the processing can be performed. Preferably, the β-1,3-glucan present in the paramylon particles is fibrillated without breaking the hydrogen bonds to form fibrils. Any known treatment capable of grinding (shearing) or pulverizing (preferably grinding (shearing)) fine particles such as paramylon particles can be employed as defibration treatment.

The fibrillation treatment can be performed using a known device such as a grinder (shearer) or a grinder. Examples of apparatuses used for fibrillation treatment include a stone grinder, a jet mill, a twin-screw kneader, a high-pressure homogenizer, a high-pressure emulsifier, a twin-screw extruder, and a bead mill. Among these, stone mills and bead mills are preferred.

The defibration treatment can be performed wet or dry. A wet fibrillation treatment is preferable because the fiberized paramylon can be more efficiently dispersed in the solution. The solvent in the wet method is not particularly limited as long as it can disperse the fiberized paramylon, and water can be preferably used.

The defibration treatment may be performed singly or in combination of two or more. In addition, it may be a partially fibrillated paramylon, and is intended in the present invention as long as it contains fibrillated paramylon.

Five. Application At least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan (hereinafter sometimes referred to as the “active ingredient of the present invention”) is associated with chylomicron production. Since it has a gene expression regulating action, it can be used as an active ingredient of a chylomicron production-related gene expression regulating agent.

Chylomicron production-related genes include genes involved in chylomicron production, such as SR-B1 (scavenger receptor class B), FABP (fatty acid binding protein 2), ACAT (acetyl-CoA acetyltransferase 1), MGAT (monoacylglycerol O -acyltransferase), Apo-A IV (apolipoprotein A4), ABCA1 (ATP binding cassette subfamily A member 1), Lipase (Phospholipase A), CLPS (colipase), PAP (phospholipid phosphatase) and the like. The products of these genes are enzymes that convert lipids in the intestinal lumen into forms that can be absorbed into the intestinal epithelial cells, receptors responsible for the absorption of lipids in the intestinal lumen into the intestinal epithelial cells, and intestinal epithelial cells. lipid transport proteins within the intestinal epithelial cells, enzymes that convert lipids within the intestinal epithelial cells into a form suitable for excretion into the circulation, or particles (chylomicrons) that excrete lipids within the intestinal epithelial cells into the circulation. They are proteins, and both function to promote chylomicron production. The active ingredient of the present invention can suppress the expression of these genes.

Since chylomicrons are produced in intestinal tissue, the tissue whose expression is to be regulated is intestinal tissue (preferably small intestinal tissue). Specifically, for example, intestinal (preferably small intestine) epithelial cells.

The active ingredient of the present invention has chylomicron production inhibitory action, lipid absorption inhibitory action in the intestine (preferably small intestine), lipid (preferably triglyceride) inhibitory action in chylomicrons, etc. based on the chylomicron production-related gene expression regulating action. have Therefore, the active ingredient of the present invention can be used for at least one selected from the group consisting of suppression of chylomicron production, suppression of lipid absorption in the intestine, and suppression of lipids in chylomicron. In one aspect, the present invention relates to an inhibitor of chylomicron production, an inhibitor of lipid absorption in the intestine, an inhibitor of lipids in chylomicron, etc., containing the active ingredient of the present invention. In the present specification, these agents may also be referred to as "the agent of the present invention" in combination with the aforementioned chylomicron production-related gene expression regulating agent.

“Suppression of lipid absorption in the intestine” means suppression of the process by which exogenous lipids (orally ingested lipids) are absorbed from the intestinal lumen into the body (circulatory system) via intestinal epithelial cells. By this suppression, the circulation and transport of lipids in the body can be suppressed from the root.

"Lipid suppression in chylomicrons" is to reduce the lipid concentration/amount in chylomicrons. By this suppression, the circulation and transport of lipids in the body can be suppressed from the root.

Based on the above actions, the active ingredient of the present invention prevents and/or improves obesity, promotes body fat burning, activates fatty acid metabolism, induces fatty acid β-oxidation, prevents and/or improves insulin resistance, and prevents and/or improves diabetes. , prevention and/or improvement of dyslipidemia, prevention and/or improvement of fatty liver, prevention and/or improvement of arteriosclerosis, improvement of endurance, prevention and/or improvement of atopic dermatitis, promotion of fatty acid metabolism, normalization of blood lipids reduction of fatty liver, promotion of energy consumption, suppression of inflammation, reduction of body fat and/or visceral fat, suppression of cholesterol, suppression of rise in blood sugar level, suppression of overweight, suppression of BMI, etc. can. The active ingredients of the present invention are preferably used for more than one of these uses (two or more, more preferably three or more, still more preferably four or more, even more preferably five or more, even more preferably six It can be used for comprehensive applications including the above).

In addition, "suppression" includes not only reducing but also suppressing the increase or deterioration of something that is on the increase or deterioration trend (reducing the increase or the degree of deterioration, not increasing or worsening).

Furthermore, the active ingredient of the present invention can be used for the following uses, purposes, and targets:
(a) Reduces visceral fat (b) Reduces body fat (c) Helps lose weight (d) Improves BMI (e) Helps reduce waist circumference (f) Increases ability to metabolize fat Increases (g) normalizes blood cholesterol levels (h) lowers blood triglycerides (i) aids excretion of excess lipids from the body (j) inhibits absorption of excess lipids into the body It can also be used for suppressing (k) the back with Venus line (l) fat limit (m) for those who are concerned about belly fat (n) for a slim belly (o) for smooth blood.

The agent of the present invention is used in various fields, for example, food compositions (including health foods, health promoting agents, dietary supplements (such as supplements)), food additives, cosmetics, cosmetic additives, pharmaceuticals, reagents, feeds, etc. can be used as The agent of the present invention is preferably an oral composition.

The form of the agent of the present invention is not particularly limited, and can take a form commonly used in each application depending on the application.

The form of the agent of the present invention, when used as a food composition, includes liquid, gel or solid foods such as juices, soft drinks, teas, soups, beverages such as soy milk, salad oils, dressings, yoghurts and jellies. , puddings, sprinkles, powdered milk for infants, cake mixes, dairy products (eg, powder, liquid, gel, solid, etc.), bread, confectionery (eg, cookies, etc.), and the like.

Examples of the form of the agent of the present invention include emulsions, cosmetic liquids, face creams, hand creams, lotions, body soaps, shampoos, rinses, cosmetic gels, packs, foundations, lip balms, and facial cleansers when the application is cosmetics. agents and the like.

Forms of the agent of the present invention include ointments, liquids for external use (liniments, lotions, etc.), sprays (aerosols for external use, pump sprays, etc.), creams, and gels when the application is a medicine. , patches (plasters, tapes such as plasters (reservoir type, matrix type, etc.), cataplasms, patches, microneedles, etc.), eye drops, ophthalmic ointments, nasal drops, suppositories, semi-rectal Formulations suitable for parenteral intake such as solid formulations and enemas (especially formulations for external use); Formulations suitable for oral intake such as pills, granules, fine granules, powders, hard capsules, soft capsules, dry syrups, liquids (including drinks, suspensions, and syrups), and jellies ( oral dosage forms).

As the form of the agent of the present invention, when the application is an additive, a health promoting agent, a nutritional supplement (such as a supplement), for example, a tablet (orally disintegrating tablet, chewable tablet, effervescent tablet, troche, jelly) drops, etc.), pills, granules, fine granules, powders, hard capsules, soft capsules, dry syrups, liquids (including suspensions and syrups), jellies, and the like.

The agent of the present invention may further contain other ingredients as necessary. Other components include food compositions (including health foods, health-promoting agents, dietary supplements (supplements, etc.)), food additives, cosmetics, cosmetic additives, pharmaceuticals, reagents, ingredients that can be added to feeds, etc. Although not particularly limited as long as it ingredients, fragrances, chelating agents, and the like.

The content of the active ingredient in the agent of the present invention depends on the application, the mode of use, the state of the application target, etc., and is not limited, but for example, 0.0001 to 100% by mass, preferably 0.001 to 50% by mass. can do.

The amount of application (e.g., administration, ingestion, inoculation, etc.) of the agent of the present invention is not particularly limited as long as it is an effective amount that expresses the desired action, and is generally 0.1 per day as the dry weight of the active ingredient. ~10000 mg/kg body weight. The above dosage is preferably applied in divided doses once or more (eg, 1 to 3 times) per day, and can be adjusted as appropriate depending on age, disease state, and symptoms.

In a preferred embodiment of the present invention, the Euglena dosage (dry weight) is preferably 100-1000 mg, more preferably 250-750 mg, and even more preferably 400-600 mg per day. Application is preferably once a day, and preferably daily. The application period is preferably 3 days or longer, more preferably 1 week or longer, still more preferably 2 weeks or longer, even more preferably 4 weeks or longer, particularly preferably 6 weeks or longer, particularly preferably 8 weeks or longer. Since the active ingredient of the present invention is naturally derived and highly safe, the upper limit of the application period is not particularly limited, but is, for example, 3 years, 1 year, 6 months, 3 months, or 2 months.

EXAMPLES The present invention will be described in detail below based on examples, but the present invention is not limited by these examples.

Reference example 1
Paramylon particles were prepared as follows.

Five flasks of liquid from the prepared Euglena gracilis EOD-1 strain (after culture but before drying) were collected, and the collected liquid was centrifuged in a centrifuge tube (500 xg, 4 minutes, room temperature). . The supernatant in the centrifugal tube was once removed and collected. The recovered supernatant was placed in a centrifuge tube to disperse the sediment in the centrifuge tube, and the whole was transferred to a graduated cylinder with a volume of 100 mL. Furthermore, the collected supernatant was added to a graduated cylinder to make up to 90 mL.

[Enzyme treatment step]
The liquid made up to 90 mL was transferred to a 200 mL beaker, and the pH of the liquid was adjusted to 3 by adding aqueous hydrochloric acid with stirring. A proteolytic enzyme (acidic protease, product name “Protease YP-SS” manufactured by Yakult Pharmaceutical Industry Co., Ltd., optimum pH 2.5 to 3.0) was added to the liquid at a concentration of 5 g/L. Enzymatic treatment was performed at 50° C. for 2 hours while stirring the liquid.

[Surfactant treatment step]
An aqueous solution of sodium dodecylsulfate was added to the liquid that had undergone the enzyme treatment step so that the concentration of sodium dodecylsulfate was 3.0% by mass/volume (w/v). While stirring the liquid containing sodium dodecyl sulfate, the pH of the liquid was adjusted to 3 by adding aqueous hydrochloric acid. Further, the liquid was stirred with a propeller stirrer (rotation speed 200 rpm) at 60° C. for 30 minutes.

[Separation process]
Paramylon was precipitated by centrifugation (1000×g, 2 minutes, room temperature) and separated from the liquid that had undergone the surfactant treatment step. A surfactant treatment step was further performed in the same manner, except that the concentration of sodium dodecyl sulfate was changed to 1.0 mass/volume % and the pH was not adjusted. After that, the separation step was performed in the same manner as described above. In this manner, the surfactant treatment step and separation step were each performed three times.

[Washing process]
Paramylon precipitated by centrifugation in the separation step was suspended in pure water and allowed to stand at 40° C. for 10 minutes. Paramylon was then precipitated by centrifugation (1000×g, 2 minutes, room temperature). Such operations were performed a total of three times.

[Drying process]
The paramylon precipitated by centrifugation in the washing step was dried at 50° C. to obtain paramylon particles. The obtained paramylon particles were used as paramylon in the following test examples.

Test example 1. Analysis of Effect on Expression of Chylomicron-Generation-Related Genes Mice were fed with feed containing paramylon (Reference Example 1), and expression levels of chylomicrons-related genes were measured. Specifically, it was carried out as follows.

<1-1. Test method>
<1-1-1. Experimental animals and breeding conditions>
A 4-week-old male C57BL/6J mouse (manufactured by Charles River Japan) was used. After one week of preliminarily breeding with solid feed (NMF, manufactured by Oriental Yeast Co., Ltd.), the mice were divided into two groups of 10 mice each so that the body weight was uniform.

The feed used in the test is as follows. 20% lard was added to the diets of the control and test groups so that the fat energy ratio was 50%. Cellulose was added to the feed of the control group so that the dietary fiber weight ratio was 5%, and paramylon was added to the feed of the test group so that the dietary fiber weight ratio was 5%. Table 1 shows the feed composition of each group. The numerical values in Table 1 are the weight (g) of each component in 1 kg of feed.

In the test, mice were given the above feed and water ad libitum for 87 days. The breeding environment was a temperature of 22±1° C., a humidity of 50±5%, and a 12-hour light-dark cycle (light period: 8:00→20:00, dark period: 20:00→8:00). The animal was fasted for 8 hours on the final day of the test and euthanized with isoflurane/carbon dioxide gas. The ileum was excised, stored in RNA later (Qiagen), and used as a sample for RNA extraction.

<1-1-2. Measurement of Chylomicron Production-Related Gene Expression>
RNA was extracted from the ileum and liver using the RNeasy mini kit (Qiagen), and the mRNA expression level of genes related to chylomicron production was measured using a microarray method (array: SurePrint G3 Mouse GE 8x60K (Agilent), equipment: GeneChi Scanner 3000 7G). It was measured using a system (Thermo Fisher Scientific) and analysis software: Transcriptome Viewer (Kurabo). The measured chylomicron production-related genes are as follows.
・SR-B1 (scavenger receptor class B, Gene ID: 12492) ・FABP (fatty acid binding protein 2, Gene ID: 14079) ・ACAT (acetyl-CoA acetyltransferase 1, Gene ID: 110446) ・MGAT (monoacylglycerol O-acyltransferase) , Gene ID: 67800), Apo-A IV (apolipoprotein A4, Gene ID: 11816), ABCA1 (ATP binding cassette subfamily A member 1, Gene ID: 11303), Lipase (phospholipase A2, Gene ID: 18778), CLPS ( colipase, Gene ID: 109791)
- PAP (phospholipid phosphatase, Gene ID: 19012).

<1-2. Results>
The results are shown in FIGS. 1 and 2. FIG. The products of the above genes are enzymes that convert lipids in the intestinal lumen into lipids in a form that can be absorbed into the intestinal epithelial cells, receptors responsible for the absorption of lipids in the intestinal lumen into the intestinal epithelial cells, lipid transport proteins in the intestinal epithelial cells, enzymes that convert lipids in the intestinal epithelial cells into a form suitable for excretion into the circulatory system, or protein constituents of particles (chylomicrons) that excrete lipids in the intestinal epithelial cells into the circulatory system and both have the function of promoting chylomicron production. As shown in FIGS. 1 and 2, paramylon intake inhibited the production of these genes, suggesting that paramylon has the effect of regulating the expression of these genes, and furthermore, has the effect of suppressing chylomicron production and reducing lipids in the intestine. It was found to have absorption inhibitory action. In addition, since Euglena contains paramylon, Euglena was also thought to have chylomicron production-related gene expression regulation, chylomicron production inhibitory action, and lipid absorption inhibitory action in the intestine.

Test example 2. Analysis of Effects on Chylomicrons Mice were fed with a feed containing paramylon (Reference Example 1), and triglyceride concentrations in chylomicrons were measured. Specifically, it was carried out as follows.

<2-1. Test method>
The rats of the control group and the test group were bred in the same manner as in Test Example 1, except that the free intake period of the feed was changed to 83 days. On the final day of the study, serum samples were taken from mice and frozen at -80°C.

Lipoproteins in 4 μL of thawed serum were separated using Skylight PakLP1-AA gel permeation columns (Skylight Biotech Inc. 300 mm×4.6 mm I.D.) connected in tandem. Lipoproteins were separated into 20 subclasses based on the Gaussian approximation, the fraction of lipoproteins with a particle size (diameter) of 90 nm was separated as the chylomicron fraction, and the triglyceride concentration of the chylomicron fraction was measured. Lipoprotein particle size was determined by the retention time of each peak observed in the chromatogram using a linear calibration curve. Triglyceride concentrations of chylomicron fractions were determined by component peak analysis based on lipoprotein particle size using a Gaussian curve fitting method.

As a result, the triglyceride concentration in the chylomicron fraction was 5.09±0.50 mg/dL in the control group and 3.74±0.28 mg/dL in the test group, with a p-value between the two groups of less than 0.05. From the above, it was found that paramylon (and Euglena containing paramylon) has a lipid-suppressing effect in chylomicrons.

Claims (15)

A chylomicron production-related gene expression regulator containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan. 2. The chylomicron production-related gene expression regulating agent according to claim 1, containing at least one selected from the group consisting of euglena, paramylon, and processed products of paramylon. It contains Euglena and/or Paramylon, and the Euglena is Euglena gracilis and/or the Paramylon is Euglena gracilis-derived paramylon,
The chylomicron production-related gene expression regulator according to claim 1 or 2. It contains the Euglena and / or paramylon, and the Euglena is Euglena gracilis EOD-1 strain (accession number FERM BP-11530) and / or the paramylon is Euglena gracilis EOD-1 strain (accession number FERM BP- 11530), which is a paramylon derived from
The chylomicron production-related gene expression regulator according to claim 1 or 2. Claim 1, for use in suppressing the expression of at least one chylomicron production-related gene selected from the group consisting of SR-B1, FABP, ACAT, MGAT, Apo-A IV, ABCA1, Lipase, CLPS, and PAP 4. The chylomicron production-related gene expression regulator according to any one of 1 to 4. The chylomicron production-related gene expression regulating agent according to any one of claims 1 to 5, for use in regulating the expression of chylomicrons production-related genes in intestinal tissue. Chylomicron production-related gene expression according to any one of claims 1 to 6, for use in at least one selected from the group consisting of suppression of chylomicrons production, suppression of lipid absorption in the intestine, and suppression of lipids in chylomicrons. regulator. The chylomicron production-related gene expression regulating agent according to claim 6 or 7, wherein the intestine is the small intestine. Obesity prevention and/or improvement, body fat burning promotion, fatty acid metabolism activation, fatty acid β-oxidation induction, insulin resistance prevention and/or improvement, diabetes prevention and/or improvement, dyslipidemia prevention and/or improvement, fatty liver prevention and/or improvement, prevention and/or improvement of arteriosclerosis, improvement of endurance, prevention and/or improvement of atopic dermatitis, promotion of fatty acid metabolism, normalization of blood lipids, suppression of fatty liver, promotion of energy consumption, inflammation for use in at least one selected from the group consisting of suppression of body fat and/or visceral fat, suppression of cholesterol, suppression of rise in blood sugar level, suppression of overweight, and suppression of BMI, claims 1 to 9. The chylomicron production-related gene expression regulator according to any one of 8. 10. The chylomicron production-related gene expression regulator according to any one of claims 1 to 9, which is a food composition, dietary supplement, food additive, or pharmaceutical. The chylomicron production-related gene expression regulator according to any one of claims 1 to 10, which is an oral composition. A chylomicron production inhibitor containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan. An inhibitor of lipid absorption in the intestine, containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan. A chylomicron lipid inhibitor containing at least one selected from the group consisting of euglena, paramylon, processed paramylon, and β-1,3-glucan. Obesity prevention and/or improvement, body fat burning promotion, fatty acid metabolism activation, fatty acid β-oxidation induction, insulin resistance prevention and/or improvement, diabetes prevention and/or improvement, dyslipidemia prevention and/or improvement, fatty liver prevention and/or improvement, prevention and/or improvement of arteriosclerosis, improvement of endurance, prevention and/or improvement of atopic dermatitis, promotion of fatty acid metabolism, normalization of blood lipids, suppression of fatty liver, promotion of energy consumption, inflammation for use in at least one selected from the group consisting of suppression of body fat and/or visceral fat, suppression of cholesterol, suppression of rise in blood sugar level, suppression of overweight, and suppression of BMI, claims 12- 15. An inhibitor according to any one of 14.

Images